Novo Nordisk's raised forecast fails to change the debate over its obesity business
First publishedAug 4, 20:17 UTC
Last updatedAug 5, 08:45 UTC · just now ago
1 outlet
MarketWatch1 outlet
CNBC Top News
2 outlets over time — hover a bar for its window & outletslast updated
Answer
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Reported by 2 outlets — CNBC Top News, MarketWatch. See all sources ↓
Read the full report at CNBC Top News ↗
Why it matters
2 outlets are covering this world story — one to watch as reporting develops.
In brief
- What's the story?
- Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
- How widely is it covered?
- 2 outlets, average source rating 7.0/10.
- When was it last updated?
- just now ago.
Different angles across outlets
Coverage map
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card2 outlets1CoverageScouting report
Novo Nordisk stock is sliding again — and the Wegovy pill’s surprise miss is partly to blame
Sources2TypeCoverage
Related in the knowledge graph
Sources (2)
Avg source rating 7.0/10Processing cluster
A1A2A3B1B2B3